Adage Capital Partners’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-5,160,000
| Closed | -$4.7M | – | 896 |
|
|
2025
Q1 | $4.7M | Hold |
5,160,000
| – | – | 0.01% | 708 |
|
|
2024
Q4 | $14.3M | Sell |
5,160,000
-513,629
| -9% | -$1.42M | 0.03% | 520 |
|
|
2024
Q3 | $29.7M | Sell |
5,673,629
-55,227
| -1% | -$289K | 0.05% | 347 |
|
|
2024
Q2 | $25.6M | Buy |
5,728,856
+400,000
| +8% | +$1.78M | 0.05% | 372 |
|
|
2024
Q1 | $40.8M | Sell |
5,328,856
-208,644
| -4% | -$1.6M | 0.08% | 277 |
|
|
2023
Q4 | $23.6M | Hold |
5,537,500
| – | – | 0.05% | 379 |
|
|
2023
Q3 | $23.3M | Buy |
5,537,500
+1,287,500
| +30% | +$5.41M | 0.05% | 351 |
|
|
2023
Q2 | $23.7M | Sell |
4,250,000
-15,138
| -0.4% | -$84.3K | 0.05% | 362 |
|
|
2023
Q1 | $24.4M | Buy |
4,265,138
+1,165,000
| +38% | +$6.68M | 0.05% | 367 |
|
|
2022
Q4 | $3.26M | Buy |
3,100,138
+503,466
| +19% | +$529K | 0.01% | 784 |
|
|
2022
Q3 | $6.96M | Buy |
2,596,672
+50,000
| +2% | +$134K | 0.02% | 729 |
|
|
2022
Q2 | $12.1M | Buy |
2,546,672
+800,000
| +46% | +$3.82M | 0.03% | 619 |
|
|
2022
Q1 | $7.14M | Buy |
1,746,672
+147,644
| +9% | +$604K | 0.01% | 783 |
|
|
2021
Q4 | $10.9M | Buy |
1,599,028
+131,200
| +9% | +$895K | 0.02% | 667 |
|
|
2021
Q3 | $17M | Buy |
1,467,828
+179,156
| +14% | +$2.08M | 0.03% | 530 |
|
|
2021
Q2 | $22M | Buy |
1,288,672
+199,000
| +18% | +$3.39M | 0.04% | 432 |
|
|
2021
Q1 | $21.6M | Buy |
1,089,672
+193,000
| +22% | +$3.82M | 0.04% | 425 |
|
|
2020
Q4 | $18.5M | Buy |
896,672
+96,672
| +12% | +$2M | 0.04% | 430 |
|
|
2020
Q3 | $21M | Buy |
+800,000
| New | +$21M | 0.05% | 363 |
|